#SARS-CoV-2

Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.

Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.

Older and immunocompromised people and those with underlying health conditions could benefit most from additional shots.

Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.

Boosters further reduce the risk of severe illness and can help curb coronavirus transmission.

Vaccine effectiveness for children ages 5 to 11 was 91%, and serious side effects are rare.

Co-occurring health disorders appear to contribute to increased risk, NIH study suggests.

A steady stream of spurious claims about COVID-19 vaccines and treatments swirl around the public consciousness.

Recommendation includes people over 65, those with underlying medical conditions and those with occupational risk.

Third dose OK’d for people over 65, those at risk for severe COVID-19 and those at high risk of exposure to the coronavirus.

The committee voted against third shot for all adults, however, casting doubts on Biden’s booster plan.

Full approval could encourage more people to get vaccinated and raises the prospect of off-label use.

The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.

Trial will assess antibody response in people who did not respond to two-dose regimen.

An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.

Previous studies of the association between tenofovir and COVID-19 outcomes in people with HIV have yielded mixed results.